FacebookTwitterGoogle+RedditEmail

Obama’s Latest FDA Nominee: No Hidden Big Pharma Links, They Are All in Plain Sight

by

The FDA has been called an arm of the drug industry because of how often it smiles on questionable new drugs and new drug approvals only to issue greater warnings or even withdraw them after the drugs made billions. Remember Vioxx, Baycol, Trovan, Meridia, Seldane, Hismanal and Darvon? They are not around anymore. Why? Remember how popular statins, brand name asthma and psychiatric drugs and GERD drugs were? Once they went off patent, the FDA “discovered” serious side effects and began to list warnings. Sorry about that.

There is a stereotype of backwoods courtroom “justice” in which prosecutors and defense attorneys who appeared to be adversarial leave arm in arm and go for a beer after a judicial decision. No hard feelings. The same collegiality oozes at FDA hearings with FDA staffers seeming to suck up to industry, perhaps for jobs in which they return to squeeze their prior colleagues. (Who remembers former Texas Governor Rick Perry’s chief of staff leaning on Perry to vaccinate all the state’s girls with the Merck vaccine Gardasil after he left for industry?)

FDA advisory panels, whose recommendations the FDA usually follows, are supposed to include “patient representatives” to see that the public’s interests are balanced against Big Pharma consultants. So many doctors and researchers now live on 5 and 6 digit drug company stipends, the FDA actually relaxed conflict of interest rules a few years ago–it could not find enough unlinked doctors!

But the “patient representatives” can be a sham. At one meeting I attended, one “patient representative” was a member of the drug industry-funded National Alliance on Mental Illness (NAMI) which was investigated by Congress for its hidden Pharma income and many consider a front group. The other so-called patient representative” had given keynote speeches at NAMI. So much for transparency.

Because of the huge amount of money to be made from a blockbuster drug like Lipitor—it was the best selling drug in the world—there is a natural tension between drug companies who want to hurry the march to Wall $treet and drug regulators who want to slow it down to protect the public.

That is why the nomination of unapologetic drug industry supporter, Robert M. Califf, for FDA Commissioner is so concerning. A disclosure statement on the website of Duke Clinical Research Institute list 25 drug companies Califf receives “research” funds from including drug giants like Johnson & Johnson, Lilly, Merck, Schering Plough and GSK.

Califf has gone on record that collaboration between industry and regulators is a good thing.  He told NPR, “Many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study.” What?

He is known for defending Vioxx which is reported to have caused at least 50,000 heart attacks and events before its withdrawal. (Merck is said to have known about Vioxx’ cardio effects but marketed the blockbuster drug anyway.)

Califf was instrumental in the Duke drug trial of the blood thinner Xarelto and a cheerleader of the drug despite medical experts’ objections to its approval and 379 subsequent deaths. Duke, where Califf directed clinical research, is still recovering from a major research fraud scandal that resulted in terminated grants, retracted papers and a Sixty Minutes special. It is the least appropriate place from which to choose an FDA Commissioner.

If approved as FDA Commissioner, as many expect, will Califf recuse himself from decisions on the dozens of drugs whose manufacturers pay him? Or will he rule on them anyway? Either way, his nomination is a slap in the face of every honest doctor, researcher and regulator and the public that puts its trust in the FDA. In fact, if the FDA Commissioner is funded by industry, why have an FDA?

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:
Weekend Edition
May 27, 2016
Friday - Sunday
John Pilger
Silencing America as It Prepares for War
Rob Urie
By the Numbers: Hillary Clinton and Donald Trump are Fringe Candidates
Paul Street
Feel the Hate
Daniel Raventós - Julie Wark
Basic Income Gathers Steam Across Europe
Andrew Levine
Hillary’s Gun Gambit
Jeffrey St. Clair
Hand Jobs: Heidegger, Hitler and Trump
S. Brian Willson
Remembering All the Deaths From All of Our Wars
Dave Lindorff
With Clinton’s Nixonian Email Scandal Deepening, Sanders Must Demand Answers
Pete Dolack
Millions for the Boss, Cuts for You!
Peter Lee
To Hell and Back: Hiroshima and Nagasaki
Gunnar Westberg
Close Calls: We Were Much Closer to Nuclear Annihilation Than We Ever Knew
Karl Grossman
Long Island as a Nuclear Park
Binoy Kampmark
Sweden’s Assange Problem: The District Court Ruling
Robert Fisk
Why the US Dropped Its Demand That Assad Must Go
Martha Rosenberg – Ronnie Cummins
Bayer and Monsanto: a Marriage Made in Hell
Brian Cloughley
Pivoting to War
Stavros Mavroudeas
Blatant Hypocrisy: the Latest Late-Night Bailout of Greece
Arun Gupta
A War of All Against All
Dan Kovalik
NPR, Yemen & the Downplaying of U.S. War Crimes
Randy Blazak
Thugs, Bullies, and Donald J. Trump: The Perils of Wounded Masculinity
Murray Dobbin
Are We Witnessing the Beginning of the End of Globalization?
Daniel Falcone
Urban Injustice: How Ghettos Happen, an Interview with David Hilfiker
Gloria Jimenez
In Honduras, USAID Was in Bed with Berta Cáceres’ Accused Killers
Kent Paterson
The Old Braceros Fight On
Lawrence Reichard
The Seemingly Endless Indignities of Air Travel: Report from the Losing Side of Class Warfare
Peter Berllios
Bernie and Utopia
Stan Cox – Paul Cox
Indonesia’s Unnatural Mud Disaster Turns Ten
Linda Pentz Gunter
Obama in Hiroshima: Time to Say “Sorry” and “Ban the Bomb”
George Souvlis
How the West Came to Rule: an Interview with Alexander Anievas
Julian Vigo
The Government and Your i-Phone: the Latest Threat to Privacy
Stratos Ramoglou
Why the Greek Economic Crisis Won’t be Ending Anytime Soon
David Price
The 2016 Tour of California: Notes on a Big Pharma Bike Race
Dmitry Mickiewicz
Barbarous Deforestation in Western Ukraine
Rev. William Alberts
The United Methodist Church Up to Its Old Trick: Kicking the Can of Real Inclusion Down the Road
Patrick Bond
Imperialism’s Junior Partners
Mark Hand
The Trouble with Fracking Fiction
Priti Gulati Cox
Broken Green: Two Years of Modi
Marc Levy
Sitrep: Hometown Unwelcomes Vietnam Vets
Lorenzo Raymond
Why Nonviolent Civil Resistance Doesn’t Work (Unless You Have Lots of Bombs)
Ed Kemmick
New Book Full of Amazing Montana Women
Michael Dickinson
Bye Bye Legal High in Backwards Britain
Missy Comley Beattie
Wanted: Daddy or Mommy in Chief
Ed Meek
The Republic of Fear
Charles R. Larson
Russian Women, Then and Now
David Yearsley
Elgar’s Hegemony: the Pomp of Empire
FacebookTwitterGoogle+RedditEmail